Tempest Therapeutics is developing first-in-class small molecule product candidates with broad potential benefit to patients.
Location: United States, California, San Francisco
Employees: 11-50
Total raised: $70M
Founded date: 2011
Investors 4
| Date | Name | Website |
| - | New Enterp... | nea.com |
| - | LAV | lavfund.co... |
| - | F-Prime Ca... | fprimecapi... |
| - | Eight Road... | eightroads... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 29.03.2018 | Series B | $70M | - |
Mentions in press and media 6
| Date | Title | Description |
| 28.07.2026 | ‘This could be a large market’: Novo Holdings-backed Claris secures $118M for corneal disease drug | A new biotech has come into view with a $118 million series B and a vision for making the front of the eye front-of-mind. Claris Biotherapeutics emerged from stealth Tuesday with designs for a pivotal trial of its rare eye disease candidate... |
| 29.03.2021 | Tempest Therapeutics jumps onto Nasdaq in merger with struggling Millendo Therapeutics; Biohaven hits $100M milestone as it gears up for a late-stage study in migraine patients... | Less than a month after landing a Big Pharma partner on one of its lead oncology programs, Tempest Therapeutics is backflipping onto Nasdaq through a reverse merger with Millendo Therapeutics. Back in January, Mill... |
| 30.03.2018 | Term Sheet — Friday, March 30 | HEALTHCARE WARS Good morning, Term Sheet readers. Paid Content You can't secure what you can't see From ExtraHop — BOMBSHELL DEAL: Walmart is in preliminary talks to buy insurer Humana Inc, according to The Wall Street Journal. If the deal ... |
| 29.03.2018 | Tempest Therapeutics Raises $70M | SAN FRANCISCO, CA, Tempest Therapeutics today announced the completion of a $70 million Series B financing. >> Click here for more funding data on Tempest Therapeutics >> To export Tempest Therapeutics funding data to PDF an... |
| 29.03.2018 | Tempest Therapeutics Closes $70M Series B Financing | Tempest Therapeutics, Inc., a San Francisco, CA-based development-stage biotechnology company advancing small molecules that modulate anti-tumor immunity pathways, completed a $70m Series B financing. The round was led by founding investor ... |
| 28.03.2018 | Tempest Therapeutics Closes $70 Million Series B Financing | - |